Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Mutual Action of Anticancer and Antiparasitic Drugs: Are There Any Shared Targets? Publisher Pubmed



Dorosti Z1 ; Yousefi M2 ; Sharafi SM3 ; Darani HY4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Parasitology and Mycology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Shahrekord University of Medical Sciences, Shahrekord, Iran
  3. 3. Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Future Oncology Published:2014


Abstract

Parasites and cancers have some common features. It has been shown that some parasites interfere with tumor growth. In addition, they both have common antigens such as the Tn antigen. A communal action of anticancer and antiparasitic drugs has been reported. This shared action may be related to common targets for these drugs in cancers and parasites. In this paper, mutual action of anticancer and antiparasitic drugs, with the aim of discussing shared targets of these drugs, has been reviewed. © 2014 Future Medicine Ltd.
Related Docs
View other Related Docs
1. Parasites and Cancers: Parasite Antigens As Possible Targets for Cancer Immunotherapy, Future Oncology (2012)
2. Anti-Cancer Immunoprotective Effects of Immunization With Hydatid Cyst Wall Antigens in a Non-Immunogenic and Metastatic Triple-Negative Murine Mammary Carcinoma Model, International Immunopharmacology (2021)
3. Parasites As Potential Targets for Cancer Immunotherapy, Journal of Cancer Research and Clinical Oncology (2023)
4. Effect of Two Hydatid Cyst Antigens on the Growth of Melanoma Cancer in C57/Black Mice, Journal of Parasitic Diseases (2016)
5. Low Titer of Antibody Against Toxoplasma Gondii May Be Related to Resistant to Cancer, Journal of Cancer Research and Therapeutics (2015)
6. Monoclonal Antibodies Production Against a 40Kda Band of Hydatid Cyst Fluid, Recent Patents on Biotechnology (2018)
7. Parasites and Immunotherapy: With or Against?, Journal of Parasitic Diseases (2016)
8. Inhibition of Mouse Colon Cancer Growth Following Immunotherapy With a Fraction of Hydatid Cyst Fluid, Experimental Parasitology (2023)
Experts (# of related papers)
View all Related Experts
Hossein Yousofi Darani (15)
Mohammad Reza Mofid (4)
Other Related Docs
9. Effect of Alive Protoscoleces of Hydatid Cyst on the Growth of Melanoma Cells in Mouse Model, Journal of Isfahan Medical School (2014)
10. Human Anti-Toxoplasma Antibodies Attach Strongly to Breast Cancer Cells, International Journal of Cancer Management (2023)
11. Effect of Hydatid Cyst Antigens Polyspecific Antisera on Breast Cancer Cells (4T1) Growth in Cell Culture Medium, International Journal of Environmental Health Engineering (2022)
12. Investigating the Reaction of Antisera Against Hydatid Cyst Antigens With the Surface of Breast Cancer (4T1), Melanoma (B16f10), and Normal Spleen Cells Using Flow Cytometry Technique, Journal of Isfahan Medical School (2018)
13. Anti-Toxoplasma Gondii Antibodies Attach to Mouse Cancer Cell Lines But Not Normal Mouse Lymphocytes, Biomedical Reports (2019)
14. Effects of Toxoplasma Gondii and Toxocara Canis Antigens on Wehi-164 Fibrosarcoma Growth in a Mouse Model, Korean Journal of Parasitology (2009)
15. Identifying the Most Effective Hydatid Cyst Fluid Fraction for Anticancer Vaccination of 4T1 Breast Tumor-Bearing Mice, International Journal of Preventive Medicine (2019)
16. Effect of Hydatid Cyst Antigens on Inhibition of Melanoma Cancer Growth in Mouse Model, Cellular and Molecular Biology (2018)
17. Biodegradable and Biocompatible Subcutaneous Implants Consisted of Ph-Sensitive Mebendazole-Loaded/Folic Acid-Targeted Chitosan Nanoparticles for Murine Triple-Negative Breast Cancer Treatment, Journal of Nanobiotechnology (2022)